약물 남용 검사 시장 보고서 : 제품별, 시료별, 최종사용자별, 지역별(2025-2033년)

The global drug abuse testing market size reached USD 7.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.5 Billion by 2033, exhibiting a growth rate (CAGR) of 5.64% during 2025-2033.

Drug abuse is the deliberate consumption of illegal substances or overindulgence of prescribed psychoactive or performance-enhancing chemicals and over-the-counter (OTC) medications. It can affect the mind and body and lead to various disorders like addiction. As a result, it is diagnosed among individuals using different testing methods to provide effective treatment for related disorders. Drug abuse testing also assists in managing acute mental status and seizure cases in the emergency room and identifying children and newborns at risk of exposure to illicit drugs. Nowadays, it finds application in workplaces before hiring an applicant.

Drug Abuse Testing Market Trends:

Presently, drugs like opiates, cannabinoids, cocaine, lysergic acid diethylamide (LSD), barbiturates, amphetamines, alcohol, diazepam, and ketamine are abused for their mind-altering characteristics, non-therapeutic and medicinal uses, and other purposes, including weight loss and enhancing athletic performance. This can lead to drug dependence and substance use disorder, which represents one of the key factors driving the demand for drug abuse testing across the globe. Apart from this, drug abuse can create significant safety and health hazards and decrease the productivity and morale of an individual. This, in turn, is positively influencing the use of drug abuse testing to screen employees and job applicants, provide a safe workplace, and comply with strict government laws and regulations. Moreover, substantial growth in pain management and opioid dependency clinics is catalyzing the demand for urine drug testing worldwide. Furthermore, leading companies are offering automated testing and analysis for drugs of abuse. These companies are also offering at-home use kits for instant drug abuse tests. This, along with the thriving e-commerce industry, is impelling the growth of the market.

Key Market Segmentation:

Breakup by Product:

• Analyzers
  • Immunoassays Analyzers
  • Chromatographic Devices
  • Breath Analyzers
• Rapid Testing Devices
  • Urine Testing Devices
  • Oral Fluid Testing Devices
• Consumables
• Laboratory Services

Breakup by Sample:

• Urine
• Oral Fluid (Saliva)
• Hair
• Breath
• Others

Breakup by End User:

• Hospitals
• Diagnostic Laboratories
• Forensic Laboratories
• Workplaces
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Dragerwerk AG & Co. KGaA, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings, Omega Laboratories Inc., Quest Diagnostics Incorporated, Siemens AG, Thermo Fisher Scientific Inc. and United States Drug Testing Laboratories Inc.

Key Questions Answered in This Report:

• How has the global drug abuse testing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global drug abuse testing market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the sample?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global drug abuse testing market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Drug Abuse Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Analyzers
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Immunoassays Analyzers
    • 6.1.2.2 Chromatographic Devices
    • 6.1.2.3 Breath Analyzers
  • 6.1.3 Market Forecast
• 6.2 Rapid Testing Devices
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Urine Testing Devices
    • 6.2.2.2 Oral Fluid Testing Devices
  • 6.2.3 Market Forecast
• 6.3 Consumables
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Laboratory Services
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Sample

• 7.1 Urine
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Oral Fluid (Saliva)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Hair
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Breath
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Laboratories
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Forensic Laboratories
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Workplaces
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Bio-Rad Laboratories Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Danaher Corporation
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Dragerwerk AG & Co. KGaA
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 F. Hoffmann-La Roche AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 SWOT Analysis
  • 14.3.6 Laboratory Corporation of America Holdings
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Omega Laboratories Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Quest Diagnostics Incorporated
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Siemens AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Thermo Fisher Scientific Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 United States Drug Testing Laboratories Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio